GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » Shares Outstanding (EOP)

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Shares Outstanding (EOP) : 477.8 Mil (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Staidson (Beijing) Biopharmaceuticals Co's shares outstanding for the quarter that ended in Jun. 2024 was 477.8 Mil.

Staidson (Beijing) Biopharmaceuticals Co's quarterly shares outstanding stayed the same from Mar. 2024 (477.8 Mil) to Jun. 2024 (477.8 Mil).

Staidson (Beijing) Biopharmaceuticals Co's annual shares outstanding increased from Dec. 2022 (475.4 Mil) to Dec. 2023 (477.8 Mil). It means Staidson (Beijing) Biopharmaceuticals Co issued new shares from Dec. 2022 to Dec. 2023 .


Staidson (Beijing) Biopharmaceuticals Co Shares Outstanding (EOP) Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co Shares Outstanding (EOP) Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 476.04 476.04 476.04 475.36 477.77

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 475.36 477.77 477.77 477.77 477.77

Competitive Comparison of Staidson (Beijing) Biopharmaceuticals Co's Shares Outstanding (EOP)

For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staidson (Beijing) Biopharmaceuticals Co's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Staidson (Beijing) Biopharmaceuticals Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Staidson (Beijing) Biopharmaceuticals Co's Shares Outstanding (EOP) falls into.



Staidson (Beijing) Biopharmaceuticals Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Staidson (Beijing) Biopharmaceuticals Co  (SZSE:300204) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Staidson (Beijing) Biopharmaceuticals Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Staidson (Beijing) Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
Executives
Zhang Hong Shan Supervisors
Zheng Hong Supervisors
Cheng Jiang Hong Executives
Feng Yu Jing Executives
Ma Li Na Secretary, Director
Zhou Zhi Wen Director
Wang Huan Securities Affairs Representative
Zhang Rong Qin Executives
Xu Jiang Ping Executives
Cao Hai Yan Supervisors
Sun Yan Fang Executives
Jiang Li Xin Director
Gu Jian Ping Director
Xu Xiang Qing Supervisors
Gu Zhen Qi Director

Staidson (Beijing) Biopharmaceuticals Co Headlines

No Headlines